3/24/2014. Applying Principles of Antimicrobial Stewardship to Effective Patient Care
|
|
- Juniper Riley
- 5 years ago
- Views:
Transcription
1 Applying Principles of Antimicrobial Stewardship to Effective Patient Care David J. Feola, Pharm.D., Ph.D. Associate Professor, Pharmacy Practice and Science University of Kentucky College of Pharmacy CE Credit in Five Easy Steps! 1. Scan your badge as you enter each session. 2. Carry your Evaluation Packet to every session so you can add session evaluation forms to it. 3. Track your hours on the Statement of Session Attendance Form as you go. 4. At your last session, total the hours and sign both pages of your Statement of Session Attendance Form. Keep the PINK copy for your records. Put the YELLOW and WHITE copies in your Evaluation Packet. Make sure a completed Session Evaluation Form is in your Evaluation Packet for each session you attended. Missing one? Extras are in a file near Registration. 5. Complete the General Attendance Evaluation Form located in your Evaluation Packet and place it back in your envelope. Write your name on the outside of your Evaluation Packet envelope, seal it, and drop it in the box near Registration. Applying for Pharmacy CPE? If you have not yet registered for an NABP e Profile ID, please visit to do so before submitting your packet. You must enter your NABP e Profile ID in order to receive CE credit this year! 3/24/ Disclosure Slide The speaker declares no conflicts of interest or financial interest in any service or product mentioned in this program. Clinical trials and off label/investigational uses will not be discussed during this presentation. 3/24/
2 Learning Objectives 1. Describe current trends in antimicrobial resistance patterns among problem pathogens 2. Explain antimicrobial stewardship practices, their impact on the spread of resistance, and how they can be implemented in hospital out outpatient infusion settings 3. Discuss how emerging resistance problems impact treatment and therapeutic decision making 4. Describe methods of intervention to ensure optimization of antimicrobial therapy in the home setting Antimicrobial resistance: a crisis in medicine INTRODUCTION 5 Modern Healthcare, August 7, 2006, page 36 Protesting infections from MRSA 2
3 Why Stewardship is Needed Antimicrobial resistance results in Increased morbidity/mortality Increased healthcare costs Practices in antimicrobial use often inadequate, not routinely implemented Up to 50% antimicrobial prescribing inappropriate Causal relationship between antimicrobial use and emergence of resistance Sulfa, BL, AG TCN, MAC, Vanc, FQ No new classes. Modify existing agents. PCN-resistant S. aureus MRSA LZD DAP TIG VRE CTL VISA in 7 states MDR Gram (-), metallo-β-lactamases, carbapenemases A Disturbing Trend Half of companies END ID drug discovery LZD-R S. aureus VRSA Marketed Antibacterial Agents FDA 3
4 Bad Bugs, No Drugs, No ESKAPE ESKAPE pathogens Enterococcus Staphylococcus Klebsiella Acinetobacter Pseudomonas ESBL producers 2011 IDSA update Of the compounds active vs. resistant Gram negative bacteria in clinical development, NONE have activity against bacteria resistant to all currently available drugs No ongoing studies for the most life threatening Gram negative infections where > 20% of patients die Boucher HW et al. CID 2009; 48:1 12. The Critical Balance Importance of appropriate empiric therapy Mortality increases when initial therapy is inappropriate Effect of broad spectrum therapy on resistance Resistance increases when broad spectrum agents are needed; Resistance has a negative impact on outcomes Collateral damage A changing landscape TRENDS IN RESISTANCE 12 4
5 Antimicrobial Use and Resistance Changes in use parallel changes in resistance Patients with resistant infections more likely to have received prior antimicrobials Hospital areas of highest resistance associated with highest antimicrobial use Increased duration of therapy increases likeliness of colonization with resistant organisms Shales DM et al. CID 1997;25: Correlation: Use and Resistance Lepper PM et al. Antimicrob Agents Chemother 2002;46: Collateral Damage Oximinocephalosporins Cefotaxime, ceftazidime, ceftriaxone cause Extended spectrum beta lactamase production Selection of stably derepressed isolates in SPACE bacteria Selection of VRE Contribution to MRSA emergence Increased cases of Clostridium difficile associated diarrhea/colitis Dancer SJ. J Antimcirobial Chemother 2001; 48:
6 Perilous Cycle: KPC Example Resistant Pathogen ESBL producing E. coli, K. pneumo, SPACE KPC Antimicrobial Resistance ESBL production Carbapenemase development Infection Unknown pathogen ESBL producing bacteria KPC producing infection Antimicrobial Use Oximinocephalosporins Carbapenems????? TEM and SHV Lactamases Extended spectrum beta lactamases (ESBL) Mutants of classical enzymes Hydrolyze most extended spectrum cephalosporins and aztreonam Carbapenems are spared Inhibited by clavulanic acid Organisms that produce ESBLs Klebsiella, E. coli, other Enterobacteriaceae and non fermenting Gram negative bacteria Livermore DM. Clin Microbiol Inf. 2008;14:S3 10. Livermore DM et al. J Antimicrob Chemother. 2001;48(suppl): Molecular Basis of ESBLs Amino acid position Ceftazidime Enzyme MIC (μg/ml) TEM 1 <0.12 Glu Arg Glu TEM Glu Ser Glu TEM Glu Ser Lys TEM 26 >256 Lys Ser Glu Modified from Rice LB. Pharmacotherapy. 1999;19:120S 128S. 6
7 Chromosomal, Inducible AmpCs Produced by the SPACE Bacteria Serratia marcescens Pseudomonas aeruginosa Acinetobacter species Citrobacter species Enterobacter species β lactamase under the control of the ampc gene (turn on) and repressor gene (turn off) Mutation is loss of the repressor gene terminology is the isolate becomes stably de repressed Drugs of choice: carbapenems, cefepime Bush, K. Clin Infect Dis 2001; 32: Stable Derepression Selection During Therapy Resistant Strain Rare Resistant Strain Dominant Selection of stable derepressed mutants: susceptible when tested, then resistance 3 days later Carbapenemases Serine lactamases KPC All plasmid mediated Metallo lactamases (MBL) VIM, IMP, NDM Aztreonam retains activity Usually co expressed with other resistance mechanisms New carbapenem breakpoints in 2010 Combination studies in vitro, in vivo Suggest optimized PK with extended infusion Livermore DM, Woodford N. Trends Microbiol. 2006;14: Bonomo RA, Szabo D. Clin Infect Dis. 2006;43(suppl 2):S49 S56. 7
8 PCN Binding Proteins MRSA loss of the target site PBP2 which is replaced by PBP2a meca gene, associated with other resistance genes in the Staphylococcal chromosome cassette (SCCmec) PBP2a confers resistance to all beta lactams Streptococcus pneumoniae PCN resistance when mutations in 4 PBPs If PCN resistant, increased macrolide resistance, FQ resistance still low CA MRSA vs. HA MRSA Characteristic CA MRSA HA MRSA Susceptibility Chloramphenicol Usually susceptible Frequently resistant Clindamycin Usually susceptible Frequently resistant Erythromycin Usually resistant Usually resistant Fluoroquinolone Geographic variability Usually resistant TMP/SMZ Usually susceptible Usually susceptible SCC mec type IV II Lineage USA 300, USA 400 USA 100, USA 200 Toxins More Fewer PVL Common Rare Weber JT. CID 2005;41 Vancomycin Glycopeptide antimicrobial that inhibits transpeptidation reaction D ala D ala Mechanisms of resistance: change in bacterial target D ala D lac (VanA, VanB) D ala D ser (VanC) Enterococcus sp. E. faecium incidence of resistance higher that E. faecalis VanA gene is on a plasmid Am J Health Syst Pharm 2000;57:S4 9 Clin Pharmacokinet 2004;43: Clin Infect Dis 2006; 2006; 42:S35 9 8
9 S. pneumoniae Susceptibility Judicious use of antimicrobials can make an impact STEWARDSHIP PRACTICES 26 Definition: Antimicrobial Stewardship Infection control plus antimicrobial management Appropriate antimicrobial selection, dosing, route, and duration System selection of antimicrobials that cause the least collateral damage MRSA ESBLs Clostridium difficille Stable derepression Metallo beta lactamases and other carbapenemases VRE 9
10 Goals of Stewardship Primary goal Optimize clinical outcome/minimize unintended consequences of antimicrobial use Secondary goal Reduce healthcare costs without adversely impacting quality of care Core Members of the Team Infectious disease physician (Director or Codirector) Clinical pharmacist with infectious disease training (Co director or core member) Other members of the team Microbiologist Information system specialist Infection control professional Hospital epidemiologist Active Core Strategies Prospective audit with intervention and feedback to reduce inappropriate antimicrobial use Formulary restriction and pre authorization leading to reductions in antimicrobial use and cost NOTE neither of these strategies are mutually exclusive 10
11 Grams per 1000 Patient Days Formulary Restriction: Example Year Third Generation Cephalosporins Cefepime Ceftazidime Resistant K Pneumoniae % Ceftazidime Resistant K Pneumoniae Isolates After initiation of formulary restriction Third generation cephalosporins use decreased Cefepime use remained stable Rates of ceftazidime resistant Klebsiella pneumoniae decreased Martin CA et al. Am J Health Syst Pharm. 2005;62: Additional Strategies Streamlining or de escalation therapy Based on culture results, elimination of redundant therapy Decreases exposure and cost Dose optimization Based on PK/PD parameters Includes patient characteristics, causative organism, site of infection, characteristics of the drug Additional Strategies Educational programs, active intervention Provides foundation of knowledge Parenteral to oral conversion When the patient s condition allows Development of clinical criteria allowing conversion Guidelines and clinical pathways Seek multi disciplinary involvement and approval Incorporate local antimicrobial resistance patterns 11
12 Assessments Drug specific Antimicrobial consumption/cost Appropriate use Adverse events Resistance patterns/development Clinical outcomes measurements Cure vs. failure (clinical, microbiologic) Super infection rate Re infection rate Patel D et al. Exp Rev Anti Infect Ther 2008; 6: Fishman N. Am J Inf Contr 2006;34:S55 63 Limited Small Hospital Data Stewardship program in community hospital 535 bed, not university affiliated Prospective audit, targeted 8 antimicrobials Retrospective review of 510 antimicrobial orders, compared to order set before implementation 63% deemed appropriate,18% required de escalation, 5% required direct consultation Before After P value Death rate within 30 days 20.7% 16.0% 0.11 C. difficile infection rate 12.4% 5.8% <0.01 Total antimicrobial costs $1,503,748 $1,274,837 Antimicrobial cost per patient day $10.16 $8.81 Malani AN et al. Am J Inf Contr 2012 May 9 (Epub). Low Hanging Fruit Justified Targeting easily implemented interventions worthwhile 1234 bed, Ohio State University Wexner Medical Center Also reviewed literature from similar programs Focused on cost savings Method to establish program, justify costs to begin Intervention Annualized Cost Savings IV to PO conversion (linezolid, moxifloxacin, fluconazole) $242,713 Therapeutic substitution (IV vancomycin for oral use) $218,877 Batching IV antimicrobials (daptomycin) $83,991 Formulary restriction (doripenem, required pre auth) $61,000 Goff DA et al. CID 2012 Jun 7 (Epub). 12
13 How resistance impacts treatment THERAPEUTIC DECISION MAKING 37 MRSA Treatment Guidelines Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin Resistant Staphylococcus aureus Infections in Adults and Children Liu C et al. CID 2011;52:1 38. Updated guideline was of critical need Landscape changing extremely rapidly due to CA MRSA emergence Updated practice recommendations for Focus on SSTI: decision making for covering MRSA, Strep, both Treatment of other infection types including pneumonia, bone and joint, CNS Management of recurrent MRSA SSTI: treatment and decolonization Drug dosing recommendations: focus on vancomycin Abscess Treatment Simple cutaneousabscess Incision and drainage alone likely adequate Can add topical antimicrobial treatment Abscesses that warrant systemic antibiotics Severe or extensive infection (deep or multiple sites) Rapid progression of associated cellulitis Systemic signs/symptoms Associated immunosuppression Lack of response to I and D Must cover MRSA; Strep coverage not necessary 13
14 CA MRSA Prescribing Trends KY Medicaid Database Beavers C. et al. Unpublished Staph vs. Strep Cutaneous abscess, purulent cellulitis CA MRSA coverage empirically Strep coverage not necessary Non purulent cellulitis Beta hemolytic Strep coverage empirically MRSA coverage not necessary unless patient does not respond To cover both Staph and Strep Clindamycin SMX TMP plus beta lactam Linezolid Vancomycin Resistance MRSA increasing MICs to vancomycin (1 2 mcg/ml) Still susceptible, but increase in treatment failures VISA mechanism: increased cell wall structural material VRSA mechanism: MRSA acquires the VanA gene Rare in the US VSSA VISA hvisa VRSA Vancomycin MIC 2 mcg/ml: susceptible 4 8 mcg/ml: intermediate 2 mcg/ml, subpopulation with MIC 4 8 mcg/ml 16 mcg/ml: resistant Clin Pharmacokinet 2004;43: Clin Infect Dis 2006; 2006; 42:S
15 Vancomycin Dosing mg/kg every 12 hours; obtain steady state trough concentration and adjust dose/interval if needed PD parameter that correlates to efficacy is AUC/MIC Target AUC/MIC is 400 based on available data To reach this, trough target mcg/ml Mean Trough Mean AUC Low dose (troughs < 15 µg/ml) 9.4 ± 3.2* 318 ± 111* High dose (troughs 15 µg/ml) 20.4 ± 3.2* 418 ± 152* However, MIC rules the situation: with high dose vancomycin, est probability of reaching AUC/MIC > 400 MIC Percent Jeffres MN et al. Chest 2006; 130: Vancomycin Toxicity Does renal toxicity limit our ability to optimize AUC/MIC? Nephrotoxicity percentage in 3 studies analyzing different vancomycin use scenarios Trough 15 mcg/ml Trough > 15 mcg/ml Nosocomial MRSA 0% 12% > 14 days of vanco 0% 15% MRSA HCAP 30.2% 58.8% Conclusion: if S. aureus MIC > 2 mcg/ml, use alternative agent (IDSA Guidelines) Lee Such SC et al ICAAC. Abstract L 1298 Hidayat LK et al. Arch Int Med. 2006;116: Jeffres MN et al. Clin Ther 2007;29(6): Susceptibilities of ESBL Producers Agent Nonsusceptibility (%) Piperacillin/tazobactam 0 53 Amoxicillin/clavulanate Gentamicin 9 67 Tobramycin Amikacin 5 27 Ciprofloxacin Sulfamethoxazole trimethoprim Nitrofurantoin 6 29 Fosfomycin 1 9 Tigecycline 0 1 Pitout JDD. Drugs 2010;70(3):
16 Treatment: ESBL Producers Carbapenems: current drugs of choice Cefepime: more stability but reports of treatment failures Little reported experience with trimethoprim/ sulfamethoxazole, aminoglycosides and fluoroquinolones Tigecycline may be an option Paterson DL, et al. CID 2004; 39: Treatment: AmpC Producers Retrospective cohort study John s Hopkins Hospital 96 cases, cefepime vs. meropenem, 32 matched pairs AmpC producing infections (Enterobacter, Serratia, Citrobacter) Had to be susceptible to agent used Cefepime shown to be equal to meropenem therapy No difference in 30 day mortality (31.2% vs. 34.3%) No difference in LOS 93% had source control Other antibiotics? Tamma PD et al. CID 2013 online Treatment: Carbapenemase Producers Multicenter, retrospective cohort study 3 teaching hospitals in Italy 125 patients with BSI with KPC producing organisms Therapy after Susceptibilities Known Nonsurvivors Survivors Mortality Rate P Value Monotherapy % 0.02 Combination % drug Combo % Tig+colistin+meropenem % Other 3 drug combo % 0.47 Tumbarello M et al. CID 2012;55(7):
17 Treatment: Carbapenemase Producers Multicenter, retrospective cohort study Outcomes stratified based upon meropenem MIC 36 BSI treated with meropenem in combination Meropenem MIC Total Nonsurvivors Survivors Mort (%) (mg/l) Total Tumbarello M et al. CID 2012;55(7): Treatment: Carbapenemase Producers Multicenter, retrospective cohort study Combination therapy impacted 30 day mortality rate (p=0.002) Multivariate analysis 4 independent RF for mortality Presentation with shock P=0.008 Inadequate initial treatment P=0.003 High APACHE III score P<0.001 Therapy with tig+col+mero P=0.01 Patients that received combination therapy had Increased acuity High MIC s to tigecycline and colistin Meropenem given over extended infusion Tumbarello M et al. CID 2012;55(7): Issues for the home infusion clinician OPTIMIZATION IN THE HOME 51 17
18 Resistance and OPAT Risk factors for infection with resistant organisms Severity of illness Previous exposure to antimicrobial agents Underlying disease conditions Chronic renal disease, DM, PVD, skin lesions Invasive procedures Dialysis, invasive devices, urinary catheterization Repeated contact with healthcare system Previous colonization with drug resistant organisms Advanced age CDC. Multidrug Resistant Organisms in Non Hospital Healthcare Settings. Resistance and OPAT Home precautions Wash hands with soap and water after physical contact with infected person, and before leaving the home Wash towels after each use Wear disposable gloves for contact of body fluids, and wash hands after glove removal Change linens on a routine basis Clean patient environment regularly Notify all who provide care that the patient is colonized/infected with a multidrug resistant pathogen CDC. Multidrug Resistant Organisms in Non Hospital Healthcare Settings. Treatment Duration CDC Get Smart Website Complete the prescribed course of treatment, even if you are feeling better. Example: CAP Guidelines 2000: We are not aware of any controlled trials that have specifically addressed the question of how long pneumonia should be treated 2007: Patients with CAP should be treated for a minimum of 5 days, should be afebrile for 48 72h, and should have no more than 1 sign of CAP associated clinical instability before discontinuation of therapy. Rice LB. CID 2008;46: (accessed Mar 29, 2011) Mandel LA et al. CID 2007;44(Suppl 2):S
19 The Issue with Infectious Diseases Research an example Animation of Tables from a meta analysis of treatment of osteomyelitis Highlights the issues with clinical trial data on which we base infectious diseases treatment decisions Limited to case series and studies with extremely small sample sizes Lazzarini L et al. Int J Inf Dis 2005;9: PK/PD Challenges in OPAT Must balance optimum dosing and convenience Continuous infusion of beta lactams increasingly studied Intricate communication required for therapeutic drug monitoring and dosage adjustment in home Adequate dosing must minimize collateral damage Treatment duration with antimicrobials an issue on the horizon Tice AD et al. CID 2004;38: Conclusions Solid understanding by home infusion clinicians of treatment issues involving Gram positive organisms can enhance care Epidemiology Resistance mechanisms Drug utilization Decolonization and hygiene measures Optimal antimicrobial use impacted greatly by OPAT Opportunities for future advancements Opportunities for individual patient interventions 57 19
20 Summary and Conclusions Antimicrobial Stewardship programs show great promise and offer new opportunities for patient care and cost impact Recommendation by both IDSA/ASHP and the CDC offer firm foundations to obtain support and funding for antimicrobial stewardship programs Optimal antimicrobial use impacted greatly by OPAT Opportunities for future advancements Opportunities for individual patient interventions 20
EXTENDED-SPECTRUM BETA-LACTAMASES EMERGING GRAM-NEGATIVE ORGANISMS
EXTENDED-SPECTRUM BETA-LACTAMASES EMERGING GRAM-NEGATIVE ORGANISMS David J. Feola, Pharm.D., Ph.D. Assistant Professor University of Kentucky College of Pharmacy Disclosures Research Funding Pfizer Objectives
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationAntimicrobial Stewardship 101
Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationAntimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationInfection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationANTIBIOTIC STEWARDSHIP
ANTIBIOTIC STEWARDSHIP S.A. Dehghan Manshadi M.D. Assistant Professor of Infectious Diseases and Tropical Medicine Tehran University of Medical Sciences Issues associated with use of antibiotics were recognized
More informationUPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM
UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationPreserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP
Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP Clinical Associate Professor Infectious Diseases Specialist The Ohio State University Medical
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationAntimicrobial Stewardship in the Hospital Setting
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 12 Antimicrobial Stewardship in the Hospital Setting Authors Dan Markley, DO, MPH, Amy L. Pakyz, PharmD, PhD, Michael Stevens, MD, MPH Chapter Editor
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationBreaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester
Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships
More informationLEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES
LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present
More informationLack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
More informationInfectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
More informationAntimicrobial Resistance
Antimicrobial Resistance Anna-Kathryn Burch, M.D. February 17, 2016 Disclosures I have nothing to disclose. Objectives Discuss antimicrobial resistance Discuss Antimicrobial Stewardship Programs (ASP)
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationMisericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014
H e a l i n g t h e B o d y E n r i c h i n g t h e M i n d N u r t u r i n g t h e S o u l Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report July December 213 Second and Third Quarters
More informationAntimicrobial Stewardship Program: Local Experience
Antimicrobial Stewardship Program: Local Experience Dr. WU Tak Chiu Associate Consultant Division of Infectious Diseases Department of Medicine Queen Elizabeth Hospital 18th January 2011 QUEEN ELIZABETH
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationMike Apley Kansas State University
Mike Apley Kansas State University 2003 - Daptomycin cyclic lipopeptides 2000 - Linezolid - oxazolidinones 1985 Imipenem - carbapenems 1978 - Norfloxacin - fluoroquinolones 1970 Cephalexin - cephalosporins
More informationWhy Antimicrobial Stewardship?
Antimicrobial Stewardship: Why and How CAPT Arjun Srinivasan, MD Associate Director for Healthcare Associated Infection Prevention Programs Division of Healthcare Quality Promotion Why Antimicrobial Stewardship?
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationOptimizing Antimicrobial Stewardship Activities Based on Institutional Resources
Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationMicrobiology Basics and Applications to Clinical Practice
Microbiology Basics and Applications to Clinical Practice LINDSEY CHILDS-KEAN, PHARMD, MPH, BCPS CLINICAL ASSISTANT PROFESSOR UNIVERSITY OF FLORIDA COLLEGE OF PHARMACY ST. PETERSBURG, FL Disclosures I
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationBugs, Drugs, and No More Shoulder Shrugs: The Role for Antimicrobial Stewardship in Long-term Care
Bugs, Drugs, and No More Shoulder Shrugs: The Role for Antimicrobial Stewardship in Long-term Care Molly Curran, PharmD, BCPS Clinical Assistant Professor The University of Texas College of Pharmacy Clinical
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationBad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016
Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November
More informationUpdates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin
More informationAntibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship
Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationPresented by: Mary McGoldrick, MS, RN, CRNI
Managing Infection Control Challenges in the Home Mary McGoldrick, MS, RN, CRNI Home Care and Hospice Consultant Saint Simons Island, GA CE Credit in Five Easy Steps! 1. Scan your badge as you enter each
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information